trending Market Intelligence /marketintelligence/en/news-insights/trending/ihqA0LgQr37vLEsooVvDnA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Aralez cutting US sales force by 32% under cost-savings plan

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Aralez cutting US sales force by 32% under cost-savings plan

Aralez Pharmaceuticals Inc. is implementing a program of cost-savings initiatives targeted at providing additional financial flexibility while maximizing the value of its assets.

Under the plan, the company will reduce its U.S. sales force by 32% and realign certain financial resources to support a phased launch of its drug Zontivity that is expected to begin in mid-April, along with a significant decrease in marketing spend on Yosprala.

The reduction in the sales force is expected to reduce the current annual run rate of operating expenses by about $7.5 million, and the company expects to incur cash severance costs of about $600,000 in the second quarter.

Aralez said it has also started other initiatives that are expected to reduce spending across the business and is in the process of finalizing its overall cost-savings plan. It plans to communicate details of this plan in its first-quarter earnings release to be issued in early May.